Current understanding of the epidemiologic and clinical characteristics of optic neuritis
- PMID: 34021411
- DOI: 10.1007/s10384-021-00840-w
Current understanding of the epidemiologic and clinical characteristics of optic neuritis
Abstract
Optic neuritis is an ocular disorder whose pathogenesis has not been fully determined, although autoimmune mechanisms have been suggested to be involved in its development. In recent years, anti-aquaporin-4 antibody (AQP4-Ab) and anti-myelin oligodendrocyte glycoprotein antibody (MOG-Ab) have been shown to play major roles in the development of optic neuritis. Because these two antibodies target different tissues, optic neuritis can be classified by the type of antibody. AQP4-Ab-positive optic neuritis responds poorly to steroid therapy and has a poor prognosis in terms of visual acuity. On the other hand, MOG-Ab-positive optic neuritis responds favorably to steroid therapy but is likely to recur when the dosage of steroids is reduced or discontinued. We first present the high incidence of idiopathic optic neuritis and discuss these relatively newer disease concepts of AQP4-Ab-positive optic neuritis and MOG-Ab-positive optic neuritis.
Keywords: AQP4; Atypical optic neuritis; MOG; Oral steroid monotherapy; Typical optic neuritis.
Similar articles
-
Epidemiologic and Clinical Characteristics of Optic Neuritis in Japan.Ophthalmology. 2019 Oct;126(10):1385-1398. doi: 10.1016/j.ophtha.2019.04.042. Epub 2019 May 6. Ophthalmology. 2019. PMID: 31196727
-
The prevalence and prognostic value of myelin oligodendrocyte glycoprotein antibody in adult optic neuritis.J Neurol Sci. 2019 Jan 15;396:225-231. doi: 10.1016/j.jns.2018.11.029. Epub 2018 Nov 28. J Neurol Sci. 2019. PMID: 30522039
-
Prevalence of Myelin Oligodendrocyte Glycoprotein and Aquaporin-4-IgG in Patients in the Optic Neuritis Treatment Trial.JAMA Ophthalmol. 2018 Apr 1;136(4):419-422. doi: 10.1001/jamaophthalmol.2017.6757. JAMA Ophthalmol. 2018. PMID: 29470571 Free PMC article. Clinical Trial.
-
Diagnosis and treatment of anti-myelin oligodendrocyte glycoprotein antibody positive optic neuritis.Jpn J Ophthalmol. 2018 Mar;62(2):101-108. doi: 10.1007/s10384-018-0561-1. Epub 2018 Feb 14. Jpn J Ophthalmol. 2018. PMID: 29445944 Review.
-
Beyond Myelin Oligodendrocyte Glycoprotein and Aquaporin-4 Antibodies: Alternative Causes of Optic Neuritis.Int J Mol Sci. 2023 Nov 5;24(21):15986. doi: 10.3390/ijms242115986. Int J Mol Sci. 2023. PMID: 37958968 Free PMC article. Review.
Cited by
-
Usage status of biologics for the chronic treatment of optic neuritis in neuromyelitis optica spectrum disorders in Japan.Jpn J Ophthalmol. 2025 Jan;69(1):81-92. doi: 10.1007/s10384-024-01129-4. Epub 2024 Oct 29. Jpn J Ophthalmol. 2025. PMID: 39470886 Free PMC article.
-
Memantine administration in patients with optic neuritis: a double blind randomized clinical trial.Graefes Arch Clin Exp Ophthalmol. 2022 Dec;260(12):3969-3975. doi: 10.1007/s00417-022-05720-8. Epub 2022 Jul 4. Graefes Arch Clin Exp Ophthalmol. 2022. PMID: 35781594 Clinical Trial.
-
Complement updates in optic neuritis.Front Neurol. 2025 Mar 26;16:1566771. doi: 10.3389/fneur.2025.1566771. eCollection 2025. Front Neurol. 2025. PMID: 40206291 Free PMC article. Review.
-
Update on glial antibody-mediated optic neuritis.Jpn J Ophthalmol. 2022 Sep;66(5):405-412. doi: 10.1007/s10384-022-00932-1. Epub 2022 Jul 27. Jpn J Ophthalmol. 2022. PMID: 35895155 Review.
References
-
- Beck RW, Cleary PA. Optic neuritis treatment trial: one-year follow-up results. Arch Ophthalmol. 1993;111:773–5. - PubMed
-
- Wakakura M, Minei-Higa R, Oono S, Matsui Y, Tabuchi A, Kani K, et al. Baseline features of idiopathic optic neuritis as determined by a multicenter treatment trial in Japan. Optic Neuritis Treatment Trial Multicenter Cooperative Research Group (ONMRG). Jpn J Ophthalmol. 1999;43:127–32.
-
- Kitley J, Leite MI, Nakashima I, Waters P, McNeillis B, Brown R, et al. Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan. Brain. 2012;135:1834–49. - PubMed
-
- Kezuka T, Ishikawa H. Diagnosis and treatment of anti-myelin oligodendrocyte glycoprotein antibody positive optic neuritis. Jpn J Ophthalmol. 2018;62:101–8. - PubMed
-
- Ishikawa H, Kezuka T, Shikishima K, Yamagami A, Hiraoka M, Chuman H, et al. Epidemiologic and clinical characteristics of optic neuritis in Japan. Ophthalmology. 2019;126:1385–98. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources